The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
Open accessPublished version of a preprint
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the rapidly unfolding coronavirus disease 2019 (COVID-19) pandemic 1,2. Clinical manifestations of COVID-19 vary, ranging from asymptomatic infection to respiratory failure. The mechanisms that determine such variable outcomes remain unresolved. Here we investigated CD4+ T cells that are reactive against the spike glycoprotein of SARS-CoV-2 in the peripheral blood of patients with COVID-19 and SARS-CoV-2-unexposed healthy donors. We detected spike-reactive CD4+ T cells not only in 83% of patients with COVID-19 but also in 35% of healthy donors. Spike-reactive CD4+ T cells in healthy donors were primarily active against C-terminal epitopes in the spike protein, which show a higher homology to spike glycoproteins of human endemic coronaviruses, compared with N-terminal epitopes. Spike-protein-reactive T cell lines generated from SARS-CoV-2-naive healthy donors responded similarly to the C-terminal region of the spike proteins of the human endemic coronaviruses 229E and OC43, as well as that of SARS-CoV-2. This results indicate that spike-protein cross-reactive T cells are present, which were probably generated during previous encounters with endemic coronaviruses. The effect of pre-existing SARS-CoV-2 cross-reactive T cells on clinical outcomes remains to be determined in larger cohorts. However, the presence of spike-protein cross-reactive T cells in a considerable fraction of the general population may affect the dynamics of the current pandemic, and has important implications for the design and analysis of upcoming trials investigating COVID-19 vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This cross-reactivity largely originates from previous exposure to circulating common cold coronaviruses [110-116].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [114]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“lymphocytes from 20% to 50% of unexposed donors display significant reactivity to SARS-CoV-2 Ag peptide pools (Figure 6).”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [114]
In the citing paper
“the T cell responses against SARS-CoV-2 are highly multi-antigenic and multi-specific, with tens of different epitopes recognized by CD4+ and CD8+ T cells in a given individual.”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [52]
In the citing paper
“The dominant cytokine produced by SARS-CoV-2-specific CD4+ T cells from COVID-19 patients is IFNγ (Braun et al., 2020; Grifoni et al., 2020; Rydyznski Moderbacher et al., 2020; Weiskopf et al., 2020), with a clear IFNγ, tumor necrosis factor (TNF), IL-2 protein signature of canonical Th1 cells (Braun et al., 2020; Rydyznski Moderbacher et al., 2020; Peng et al., 2020; Sekine et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020
In the citing paper
“In contrast, the strikingly extended absence of SARS-CoV-2-specific CD4+ T cells was associated with severe or fatal COVID-19 (>day 22 PSO in some cases) (Braun et al., 2020; Rydyznski Moderbacher et al., 2020; Tan et al., 2020a).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020
In the citing paper
“In contrast, substantial cross-reactive T cell memory has been reported, measurable in ∼28%–50% of people, depending on the study (Le Bert et al., 2020; Braun et al., 2020; Grifoni et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020
In the citing paper
“SARS-CoV-2 infection elicits a Th1 CD4+ T cell response, with IFNγ and IL-2 being the primary cytokines produced by these cells and some TNFα production as well112,126-129.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [128]
In the citing paper
“Specifically, when compared to those with mild COVID-19, patients with severe disease generated a weaker T cell response to the N-terminal portion of the SARS-CoV-2 S protein, a region that includes the critical receptor-binding domain (RBD)128.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [128]
In the citing paper
“Therefore, many individuals have existing memory T cells that were generated from endemic human coronavirus infections and can cross-react with SARS-CoV-2 epitopes, known as SARS-CoV-2 cross-reactive memory T cells128.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [128]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clustal W and Clustal X version 2.0
Larkin, M., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P., McWilliam, H., Valentin, F., Wallace, I. M., Wilm, A., López, R., et al. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm404 · Cited by 28,598
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Needleman, S. B., & Wunsch, C. D. (1970) · Journal of Molecular Biology · doi:10.1016/0022-2836(70)90057-4 · Cited by 11,288
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K. W., Bleicker, T., Brünink, S., Schneider, J. A., Schmidt, M. L., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.3.2000045 · Cited by 7,266
Self-citationVirological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Self-citationWu, J. T., Leung, K., & Leung, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30260-9 · Cited by 4,389
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., Chen, L., Li, M., Liu, Y., Wang, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00827 · Cited by 2,475
Cited by
Sorted by citations
Items 201–300 of 999
A Longitudinal Study of Immune Cells in Severe COVID-19 Patients
Payen, D. M., Cravat, M., Maadadi, H., Didelot, C., Prosic, L., Dupuis, C., Losser, M.-R., & Bittencourt, M. D. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.580250 · Cited by 77
Antunes, R. D. S., Pallikkuth, S., Williams, E., Yu, E. D., Mateus, J., Quiambao, L. G., Wang, E. W., Rawlings, S. A., Stadlbauer, D., Jiang, K., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab176 · Cited by 70
HLA-DR Marks Recently Divided Antigen-Specific Effector CD4 T Cells in Active Tuberculosis Patients
Tippalagama, R., Singhania, A., Dubelko, P., Arlehamn, C. S. L., Crinklaw, A., Pomaznoy, M., Seumois, G., Silva, A. D. D., Premawansa, S., Vidanagama, D. S., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100011 · Cited by 74
Koerber, N., Priller, A., Yazici, S., Bauer, T., Cheng, C., Mijočević, H., Wintersteller, H., Jeske, S. D., Vogel, E., Feuerherd, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27649-y · Cited by 75
Nouailles, G., Adler, J. M., Pennitz, P., Peidli, S., Alves, L. G. T., Baumgardt, M., Bushe, J., Voß, A., Langenhagen, A. K., Langner, C., et al. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01352-8 · Cited by 77
Self-citationPoston, D., Weisblum, Y., Wise, H. M., Templeton, K. E., Jenks, S. J., Hatziioannou, T., & Bieniasz, P. D. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1803 · Cited by 78
Niessl, J., Sekine, T., & Buggert, M. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101505 · Cited by 77
Gao, Y., Cai, C., Wullimann, D., Niessl, J., Rivera‐Ballesteros, O., Chen, P., Lange, J., Cuapio, A., Blennow, O., Hansson, L., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.07.005 · Cited by 73
Saletti, G., Gerlach, T. H., Jansen, J. M., Molle, A., Elbahesh, H., Ludlow, M., Li, W., Bosch, B., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2020) · Scientific Reports · doi:10.1038/s41598-020-78506-9 · Cited by 74
Parker, R., Partridge, T., Wormald, C., Kawahara, R., Stalls, V., Aggelakopoulou, M., Parker, J., Doherty, R. P., Ariosa-Morejon, Y., Lee, E., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109179 · Cited by 75
Ruhl, L., Pink, I., Kühne, J. F., Beushausen, K., Keil, J., Christoph, S., Sauer, A., Boblitz, L., Schmidt, J. J., David, S., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00819-6 · Cited by 81
Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections
Bonam, S. R., Kotla, N. G., Bohara, R. A., Rochev, Y. A., Webster, T. J., & Bayry, J. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101051 · Cited by 76
Jaganathan, S., Stieber, F., Rao, S. N., Nikolayevskyy, V., Manissero, D., Allen, N. P. C., Boyle, J., & Howard, J. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00521-8 · Cited by 74
Functional SARS-CoV-2 cross-reactive CD4 + T cells established in early childhood decline with age
Humbert, M., Olofsson, A., Wullimann, D., Niessl, J., Hodcroft, E. B., Cai, C., Gao, Y., Sohlberg, E., Dyrdak, R., Mikaeloff, F., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2220320120 · Cited by 76
Arashkia, A., Jalilvand, S., Mohajel, N., Afchangi, A., Azadmanesh, K., Salehi-Vaziri, ., Fazlalipour, M., Pouriayevali, M. H., Jalali, T., Nasab, S. D. M., et al. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2183 · Cited by 73
SARS-CoV-2 reinfection and implications for vaccine development
Nainu, F., Abidin, R. S., Bahar, M. A., Frediansyah, A., Emran, T. B., Rabaan, A. A., Dhama, K., & Harapan, H. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1830683 · Cited by 73
Wang, Y., Zheng, J., Islam, M. S., Yang, Y., Hu, Y., & Chen, X. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59534 · Cited by 71
Wyllie, D., Jones, H. E., Mulchandani, R., Trickey, A., Taylor-Phillips, S., Brooks, T., Charlett, A., Ades, A., EDSAB-HOME investigators, Moore, P., et al. (2020) · doi:10.1101/2020.11.02.20222778 · Cited by 96
Bertoletti, A., Tan, A. T., & Bert, N. L. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab006 · Cited by 69
A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection
Andreakos, E., Abel, L., Vinh, D. C., Kaja, E., Drolet, B. A., Zhang, Q., O’Farrelly, C., Novelli, G., Rodríguez‐Gallego, C., Haerynck, F., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01030-z · Cited by 71
Chandran, A., Rosenheim, J., Nageswaran, G., Swadling, L., Pollara, G., Gupta, R. K., Burton, A. R., Guerra‐Assunção, J. A., Woolston, A., Ronel, T., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100557 · Cited by 67
SARS-CoV-2 serosurvey in health care workers of the Veneto Region
Plebani, M., Padoan, A., Fedeli, U., Schievano, E., Vecchiato, E., Lippi, G., Cascio, G. L., Porru, S., & Palù, G. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-1236 · Cited by 66
Romero‐Olmedo, A. J., Schulz, A. R., Hochstätter, S., Gupta, D. D., Virta, I., Hirseland, H., Staudenraus, D., Camara, B., Münch, C., Hefter, V., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01046-z · Cited by 66
Sermet‐Gaudelus, I., Temmam, S., Huon, C., Behillil, S., Gajdos, V., Bigot, T., Lurier, T., Chrétien, D., Backović, M., Delaunay, A., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.13.2001782 · Cited by 70
Zhang, H., Deng, S., Ren, L., Zheng, P., Hu, X., Jin, T., & Tan, X. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109708 · Cited by 69
Holenya, P., Lange, P. J., Reimer, U., Woltersdorf, W. W. W., Panterodt, T., Glas, M., Wasner, M., Eckey, M., Drosch, M., Hollidt, J., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202049101 · Cited by 66
Self-citationMaringer, Y., Nelde, A., Schroeder, S. M., Schuhmacher, J., Hörber, S., Peter, A., Karbach, J., Jäger, E., & Walz, J. S. (2022) · Science Immunology · doi:10.1126/sciimmunol.add3899 · Cited by 62
Woudenberg, T., Pelleau, S., Anna, F., Attia, M., Donnadieu, F., Gravet, A., Lohmann, C., Séraphin, H., Guihéneuf, R., Delamare, C., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103495 · Cited by 64
SARS-CoV-2 infection incidence during the first and second COVID-19 waves in Italy
Vinceti, M., Filippini, T., Rothman, K. J., Federico, S. D., & Orsini, N. (2021) · Environmental Research · doi:10.1016/j.envres.2021.111097 · Cited by 73
Defending against SARS-CoV-2: The T cell perspective
Almendro-Vázquez, P., Laguna‐Goya, R., & Paz‐Artal, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107803 · Cited by 67
Li, Z., Xiang, T., Liang, B., Deng, H., Wang, H., Feng, X., Quan, X., Wang, X., Li, S., Lu, S., et al. (2021) · Frontiers in Immunology · doi:10.2139/ssrn.3914631 · Cited by 66
Immunosenescence and inflamm-ageing in COVID-19
Zinatizadeh, M. R., Zarandi, P. K., Ghiasi, M., Kooshki, H., Mohammadi, M., Amani, J., & Rezaei, N. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101818 · Cited by 69
SARS-CoV-2-specific immune response in COVID-19 convalescent individuals
Pan, Y., Jiang, X., Yang, L., Chen, L., Zeng, X., Liu, G., Tang, Y., Qian, C., Wang, X., Cheng, F., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00686-1 · Cited by 61
Havervall, S., Ng, H., Falk, A. J., Greilert‐Norin, N., Månberg, A., Marking, U. W., Laurén, I., Gabrielsson, L., Salomonsson, A., Aguilera, K., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13387 · Cited by 63
Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion
Mazzoni, A., Salvati, L., Maggi, L., Annunziato, F., & Cosmi, L. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101508 · Cited by 69
Harrington, P., Doores, K. J., Radia, D. H., O’Reilly, A., Lam, H. P. J., Seow, J., Graham, C., Lechmere, T., McLornan, D. P., Dillon, R. J., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17568 · Cited by 62
Mazzoni, A., Maggi, L., Capone, M., Spinicci, M., Salvati, L., Colao, M. G., Vanni, A., Kiros, S. T., Mencarini, J., Zammarchi, L., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.202048915 · Cited by 61
Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity
Lee, E., Sandgren, K. J., Duette, G., Stylianou, V. V., Khanna, R., Eden, J., Blyth, E., Gottlieb, D. J., Cunningham, A. L., & Palmer, S. (2020) · Journal of Virology · doi:10.1128/jvi.02002-20 · Cited by 62
Haynes, W. A., Kamath, K., Bozekowski, J. D., Baum, E., Campbell, M., Casanovas‐Massana, A., Daugherty, P. S., Cruz, C. S. D., Dhal, A., Farhadian, S., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02835-2 · Cited by 60
Brasu, N., Elia, I., Russo, V., Montacchiesi, G., Stabile, S. A., Intinis, C. D., Fesi, F., Gizzi, K., Macagno, M., Montone, M., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01313-z · Cited by 58
Exhaustion and over-activation of immune cells in COVID-19: Challenges and therapeutic opportunities
Alahdal, M., & Elkord, E. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109177 · Cited by 60
Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization
Sui, Y., Bekele, Y., & Berzofsky, J. A. (2021) · Pathogens · doi:10.3390/pathogens10020138 · Cited by 57
Kamyshnyi, O., Matskevych, V. M., Lenchuk, T., Strilbytska, O. M., Storey, K. B., & Lushchak, O. V. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112230 · Cited by 62
Age-related Differences in the Nasal Mucosal Immune Response to SARS-CoV-2
Koch, C. M., Prigge, A. D., Anekalla, K. R., Shukla, A., Umehara, H. C. D., Setar, L., Chavez, J., Abdala‐Valencia, H., Politanska, Y., Markov, N. S., et al. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0292oc · Cited by 58
Bartolo, L., Afroz, S., Pan, Y., Xu, R., Williams, L., Lin, C.-F., Tanes, C., Bittinger, K. L., Friedman, E. S., Gimotty, P. A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn3127 · Cited by 55
T cell immune memory after covid-19 and vaccination
Wang, L., Nicols, A. R., Turtle, L. C. W., Richter, A. G., Duncan, C. J. A., Dunachie, S. J., Klenerman, P., & Payne, R. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000468 · Cited by 66
Distinct antibody repertoires against endemic human coronaviruses in children and adults
Khan, T., Rahman, M., Ali, F. A., Huang, S. S. Y., Ata, M. M. A., Zhang, Q., Bastard, P., Liu, Z., Jouanguy, E., Béziat, V., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.144499 · Cited by 56
A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2
Majdoubi, A., Michalski, C., O’Connell, S. E., Dada, S., Narpala, S., Gelinas, J. P., Mehta, D., Cheung, C., Winkler, D. F. H., Basappa, M., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.146316 · Cited by 57
Goletti, D., Petrone, L., Manissero, D., Bertoletti, A., Rao, S. N., Ndunda, N., Sette, A., & Nikolayevskyy, V. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.07.005 · Cited by 68
Vikkurthi, R., Ansari, A., Pai, A. R., Jha, S. N., Sachan, S., Pandit, S., Nikam, B., Kalia, A., Jit, B. P., Parray, H. A., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01161-5 · Cited by 61
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer
Mazzotti, L., Gaimari, A., Bravaccini, S., Maltoni, R., Cerchione, C., Juan, M., González‐Navarro, E. A., Pasetto, A., Silva, D. N., Ancarani, V., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158590 · Cited by 64
COVID-19 in children: current evidence and key questions
Munro, A. P. S., & Faust, S. N. (2020) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000690 · Cited by 56
Role of arachidonic cascade in COVID-19 infection: A review
Ripon, M. A. R., Bhowmik, D. R., Amin, M. T., & Hossain, M. S. (2021) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2021.106539 · Cited by 59
Stanczak, M. A., Sanin, D. E., Apostolova, P., Nerz, G., Lampaki, D., Hofmann, M., Steinmann, D., Krohn-Grimberghe, M., Thimme, R., Mittler, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22449-w · Cited by 57
Trougakos, I. P., Terpos, E., Zirou, C., Sklirou, A. D., Apostolakou, F., Gumeni, S., Charitaki, I., Papanagnou, E., Bagratuni, T., Liacos, C., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02090-6 · Cited by 60
Pham, M. N., Murugesan, K., Banaei, N., Pinsky, B. A., Tang, M. C., Hoyte, E. G., Lewis, D. B., & Gernez, Y. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.11.022 · Cited by 56
Tiecco, G., Storti, S., Antoni, M. D., Focà, E., Castelli, F., & Quirós-Roldán, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23041987 · Cited by 59
Nelson, R. W., Chen, Y., Venezia, O. L., Majerus, R. M., Shin, D. S., MGH COVID-19 Collection & Processing Team, Carrington, M. N., Yu, X. G., Wesemann, D. R., Moon, J. J., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abl9464 · Cited by 56
NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4+ and CD8+ T cell responses
Moderbacher, C. R., Kim, C., Mateus, J., Plested, J. S., Zhu, M., Cloney-Clark, S., Weiskopf, D., Sette, A., Fries, L. F., Glenn, G. M., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci160898 · Cited by 61
A novel STING agonist for cancer immunotherapy and a SARS-CoV-2 vaccine adjuvant
Wu, J., Zhao, L., Han, B.-B., Hu, H., Zhang, B.-D., Li, W.-H., Chen, Y., & Li, Y. (2020) · Chemical Communications · doi:10.1039/d0cc06959k · Cited by 56
In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy
Petrone, L., Petruccioli, E., Alonzi, T., Vanini, V., Cuzzi, G., Fard, S. N., Castilletti, C., Palmieri, F., Gualano, G., Vittozzi, P., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.02.023 · Cited by 58
Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency
Kinoshita, H., Durkee-Shock, J. R., Jensen-Wachspress, M. A., Kankate, V. V., Lang, H., Lazarski, C. A., Keswani, A., Webber, K., Montgomery-Recht, K., Walkiewicz, M. A., et al. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-01046-y · Cited by 56
Mysore, V., Culleré, X., Settles, M. L., Ji, X., Kattan, M. W., Desjardins, M., Durbin-Johnson, B. P., Gilboa, T., Baden, L. R., Walt, D. R., et al. (2021) · Med · doi:10.1016/j.medj.2021.08.004 · Cited by 56
SARS-CoV-2 and influenza: a comparative overview and treatment implications
Manzanares, L. D., & Contreras, O. M. (2020) · Boletín Médico del Hospital Infantil de México · doi:10.24875/bmhim.20000183 · Cited by 64
Immunopathogenesis of SARS-CoV-2-induced pneumonia: lessons from influenza virus infection
Miyazawa, M. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-020-00148-1 · Cited by 54
Cassaniti, I., Percivalle, E., Bergami, F., Piralla, A., Comolli, G., Bruno, R., Vecchia, M., Sambo, M., Colaneri, M., Zuccaro, V., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.03.010 · Cited by 56
Aiello, A., Fard, S. N., Petruccioli, E., Petrone, L., Vanini, V., Farroni, C., Cuzzi, G., Navarra, A., Gualano, G., Mosti, S., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.04.034 · Cited by 54
Resolving SARS-CoV-2 CD4+ T cell specificity via reverse epitope discovery
Pogorelyy, M. V., Rosati, E., Minervina, A. A., Mettelman, R. C., Scheffold, A., Franke, A., Bächer, P., & Thomas, P. G. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100697 · Cited by 56
Pardieck, I. N., van der Sluis, T. C., van der Gracht, E. T. I., Veerkamp, D. M. B., Behr, F. M., van Duikeren, S., Beyrend, G., Rip, J., Nadafi, R., Nejad, E. B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31721-6 · Cited by 54
Wratil, P. R., Schmacke, N. A., Karakoc, B., Dulovic, A., Junker, D., Becker, M., Rothbauer, U., Osterman, A., Späth, P. M., Ruhle, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110169 · Cited by 57
Mahajan, S., Kode, V., Bhojak, K., Coral, K., Lee, K. M., Manoharan, M., Ramesh, A., Sudheendra, H., Srivastava, A., Sathian, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92521-4 · Cited by 54
Brown, B., Ojha, V., Fricke, I., Al-Sheboul, S. A., Imarogbe, C., Gravier, T., Green, M., Peterson, L., Koutsaroff, I. P., Demir, A. N., et al. (2023) · Vaccines · doi:10.3390/vaccines11020408 · Cited by 55
Immunesenescence: A Predisposing Risk Factor for the Development of COVID-19?
Hazeldine, J., & Lord, J. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.573662 · Cited by 55
Pathogenesis‐directed therapy of 2019 novel coronavirus disease
Stratton, C. W., Tang, Y., & Lu, H. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26610 · Cited by 59
Rank, A., Tzortzini, A., Kling, E., Schmid, C., Claus, R., Loell, E., Burger, R., Römmele, C., Dhillon, C., Müller, K., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153305 · Cited by 53
Trans-ethnic genome-wide association study of severe COVID-19
Wu, P., Ding, L., Li, X., Liu, S. M., Cheng, F., He, Q., Xiao, M., Wu, P., Hou, H., Jiang, M., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02549-5 · Cited by 52
The way of SARS-CoV-2 vaccine development: success and challenges
Dong, Y., Dai, T., Wang, B., Zhang, L., Zeng, L., Huang, J., Yan, H., Zhang, L., & Zhou, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00796-w · Cited by 53
Galipeau, Y., Siragam, V., Laroche, G., Marion, E., Greig, M., McGuinty, M., Booth, R. A., Durocher, Y., Čuperlović‐Culf, M., Bennett, S. A. L., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103700 · Cited by 56
SARS-CoV-2 specific memory T cell epitopes identified in COVID-19-recovered subjects
Zhao, J., Wang, L., Schank, M., Dang, X., Lu, Z., Cao, D., Khanal, S., Nguyen, L. N., Nguyen, L. N., Zhang, J., et al. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198508 · Cited by 50
Thymic Aging May Be Associated with COVID-19 Pathophysiology in the Elderly
Wang, W., Thomas, R. G., Oh, J., & Su, D. (2021) · Cells · doi:10.3390/cells10030628 · Cited by 52
Srivastava, R., Daulatabad, S. V., Srivastava, M., & Janga, S. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197090 · Cited by 52
Kim, D. S., Rowland‐Jones, S., & Gea‐Mallorquí, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.571481 · Cited by 51
Hu, C., Shen, M., Han, X., Chen, Q., Luo, L., Chen, S., Zhang, J., Gao, F., Wang, W., Wang, Y., et al. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.05.006 · Cited by 47
Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster
Brustolin, M., Rodon, J., de la Concepción, M. L. R., Ávila‐Nieto, C., Cantero, G., Pérez, M., Te, N., Noguera-Julián, M., Guallar, V., Valencia, A., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1913974 · Cited by 50
Tan, C. C. S., Owen, C. J., Tham, C. Y. L., Bertoletti, A., van Dorp, L., & Balloux, F. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.105075 · Cited by 54
Ansari, A., Arya, R. K., Sachan, S., Jha, S. N., Kalia, A., Lall, A., Sette, A., Grifoni, A., Weiskopf, D., Coshic, P., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636768 · Cited by 50
Dynamics of TCR repertoire and T cell function in COVID-19 convalescent individuals
Luo, L., Liang, W., Pang, J., Xu, G., Chen, Y., Guo, X., Wang, X., Zhao, Y., Lai, Y., Liu, Y., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00321-x · Cited by 47
Power-law population heterogeneity governs epidemic waves
Neipel, J., Bauermann, J., Bo, S., Harmon, T. S., & Jülicher, F. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239678 · Cited by 51
Banihashemi, S. R., Es‐haghi, A., Mehrabadi, M. H. F., Noofeli, M., Mokarram, A. R., Ranjbar, A., Salman, Μ. D., Hajimoradi, M., Razaz, S. H., Taghdiri, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.836745 · Cited by 48
Immunologic perturbations in severe COVID-19/SARS-CoV-2 infectionPreprint
Kuri-Cervantes, L., Pampena, M. B., Meng, W., Rosenfeld, A. M., Ittner, C. A. G., Weisman, A. R., Agyekum, R. S., Mathew, D., Baxter, A. E., Vella, L. A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.18.101717 · Cited by 50
Echeverría, G. A., Guevara, A. G., Coloma, J., Ruiz, A. M., Vasquez, M. M., Tejera, E., & de Waard, J. H. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.02.034 · Cited by 49
The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection
Moga, E., Lynton‐Pons, E., & Domingo, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904686 · Cited by 48
Mahmoodpoor, A., Hosseini, M. S., Soltani‐Zangbar, M. S., Sanaie, S., Maleki, L. A., Saghaleini, S. H., Ostadi, Z., Hajivalili, M., Bayatmakoo, Z., Haji-Fatahaliha, M., et al. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.06.001 · Cited by 47
Xu, K., Dai, L., & Gao, G. F. (2021) · International Immunology · doi:10.1093/intimm/dxab061 · Cited by 48
Heide, J., Schulte, S., Kohsar, M., Brehm, T. T., Herrmann, M., Karsten, H., Marget, M., Peine, S., Johansson, A. M., Sette, A., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009842 · Cited by 46
Horiuchi, S., Oishi, K., Carrau, L., Frere, J. J., Møller, R., Panis, M., & tenOever, B. R. (2021) · Science Immunology · doi:10.1126/sciimmunol.abm3131 · Cited by 45
Giménez, E., Albert, E., Torres, I., Remigia, M. J., Alcaráz, M. J., Galindo, M. J., Blasco, M. L., Solano, C., Forner, M. J., Redón, J., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26213 · Cited by 46
Performance of the T-SPOTⓇ.COVID test for detecting SARS-CoV-2-responsive T cells
Kruse, M., Dark, C., Aspden, M., Cochrane, D., Competiello, R., Peltz, M., Torres, L., Wrighton-Smith, P., & Dudek, M. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.073 · Cited by 42
Recruitment of highly cytotoxic CD8+ T cell receptors in mild SARS-CoV-2 infection
Wagner, K. I., Mateyka, L. M., Jarosch, S., Grass, V., Weber, S., Schober, K., Hammel, M., Burrell, T., Kalali, B. N., Poppert, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110214 · Cited by 47
Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2
Kurt, F. G. Ö., Lepper, A., Gerhards, C., Roemer, M., Lasser, S., Arkhypov, I., Bitsch, R., Bugert, P., Altevogt, P., Gouttefangeas, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1012526 · Cited by 48
Metadata
- Authors
- Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F., Baysal, E., Mangold, M., Henze, L., Lauster, R., Mall, M. A., Beyer, K., Röhmel, J., Voigt, S., Schmitz, J., Miltenyi, S., Demuth, I., Müller, M. A., Hocke, A., Witzenrath, M., Suttorp, N., Kern, F., Reimer, U., Wenschuh, H., Drosten, C., Corman, V. M., Giesecke-Thiel, C., Sander, L. E., & Thiel, A.
- Affiliations
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Charité – Universitätsmedizin Berlin (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Technische Universität Berlin (DE)
- Robert Koch Institute (DE)
- Miltenyi Biotec (Germany) (DE)
- Brighton and Sussex Medical School (GB)
- JPT Peptide Technologies (Germany) (DE)
- Corresponding author
- Sander, Leif Erik
- Thiel, Andreas
- ORCID
- Braun, Julian
- Loyal, Lucie
- Frentsch, Marco
- Wendisch, Daniel
- Georg, Philipp
- Kurth, Florian
- Hippenstiel, Stefan
- Dingeldey, Manuela
- Fauchere, Florent
- Baysal, Emre
- Mangold, Maike
- Henze, Larissa
- Mall, Marcus A.
- Beyer, Kirsten
- Voigt, Sebastian
- Demuth, Ilja
- Müller, Marcel A.
- Hocke, Andreas
- Witzenrath, Martin
- Suttorp, Norbert
- Kern, Florian
- Reimer, Ulf
- Drosten, Christian
- Corman, Victor M.
- Giesecke-Thiel, Claudia
- Sander, Leif Erik
- Thiel, Andreas
- Venue
- Nature
- Published
- 2020-07-29
- Volume
- 587
- Issue
- 7833
- Pages
- 270-274
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3045971896
- Cited by
- 1,310
- References
- 41
- Citations by year
- 2026: 16 · 2025: 37 · 2024: 91 · 2023: 143 · 2022: 283 · 2021: 480 · 2020: 259
- FWCI
- 38.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Sussex Research Online (University of Sussex) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- Deutsche Forschungsgemeinschaft (KFO 339, SFB‐TR84)
- Bundesministerium für Bildung und Forschung
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, CD4+ T cells, spike protein, cross-reactive T cells, HCoV-229E, HCoV-OC43, C-terminal epitope, T cell immunity, COVID-19 vaccine design, healthy donors
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Adult, Aged, Aged, 80 and over, Cell Line, Cross Reactions, Female, Humans, Lymphocyte Activation, Male, Middle Aged, Pneumonia, Viral, CD4-Positive T-Lymphocytes, Coronavirus Infections, Epitopes, T-Lymphocyte, Coronavirus 229E, Human, Coronavirus OC43, Human, Pandemics, Coronavirus NL63, Human, Healthy Volunteers, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
